MedScien
June 6, 2024
Chaoyi Fan, Jiayi Li, Shaohuan Yu
Lysergic acid diethylamide (LSD) is a semi-synthetic hallucinogen that induces intense hallucinogenic effects. There are various ways that hallucinations can occur, but classic psychedelics like LSD differ significantly in their effects from those caused by other means. The primary focus of current research is on activating 5-HT2A receptors within the serotonin system, which is essential for...
Fortschritte der Neurologie · Psychiatrie
June 1, 2024
Aufgrund seiner positiven subjektiven Wirkung hat Lysergsäurediethylamid (LSD) schon lange das psychiatrische Forschungsinteresse geweckt. Da aber neben gewünschten Effekten unter LSD auch Ängste keine Seltenheit sind, könnte die gleichzeitige Einnahme von MDMA (3,4-Methylendioxymethamphetamin) negative Effekte abfangen und die positiven verstärken. Straumann et al. sind dieser Hypothese...
Journal of Clinical Oncology
June 1, 2024
Amrit Baral, Yue Pan, Alberto J. Caban Martinez et al.
e22518 Background: Classic psychedelics (Peyote, Psilocybin, Mescaline, and LSD) are re-emerging in the oncology toolbox. Peyote is the oldest known psychedelic, yet underexplored in clinical research. Preclinical studies suggest its extract stimulates lymphocyte proliferation, kills tumor cells, and may regulate sleep. This study aims to estimate the prevalence of classic psychedelic use among...
Drug Testing and Analysis
June 1, 2024
Takuji Shoda, Genichiro Tsuji, Maiko Kawamura et al.
1 citation
Lysergic acid diethylamide (LSD) is a hallucinogenic compound that binds to and activates the serotonin 2A receptor and is classified as a controlled narcotic in Japan. Recently, MiPLA, an N-methyl-N-isopropyl derivative of LSD, has been detected in paper-sheet products in several countries. This study focuses on the synthesis of MiPLA and includes a comprehensive analysis involving structural...
Neuropsychopharmacology
June 1, 2024
Conor H. Murray, Joel Frohlich, Connor J Haggarty et al.
30 citations
Neural complexity correlates with one's level of consciousness. During coma, anesthesia, and sleep, complexity is reduced. During altered states, including after lysergic acid diethylamide (LSD), complexity is increased. In the present analysis, we examined whether low doses of LSD (13 and 26 µg) were sufficient to increase neural complexity in the absence of altered states of consciousness. In...
Psychedelic Medicine
June 1, 2024
Brian S. Barnett, Akhil Anand, Elizabeth N. Dewey et al.
20 citations
Though lysergic acid diethylamide (LSD) use is rising in the United States amid expanding research into the therapeutic potential of psychedelics, little scholarly work exists on whether perceived risk of trying LSD (prLSD) is changing or factors influencing prLSD among the general public. Therefore, we sought to investigate changes in prLSD from 2015 to 2019 and identify characteristics...
Addiction
May 21, 2024
Shane Darke, Johan Duflou, Amy Peacock et al.
14 citations
Abstract Background and aims Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their clinical use. The current study aimed to (1) determine the circumstances of death and case characteristics of LSD‐ and psilocybin‐related death in Australia, 2000–23; and (2) determine the toxicological profile and major autopsy findings of these...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
May 1, 2024
Mihai Avram, Felix Müller, Katrin H. Preller et al.
13 citations
While the exploration of serotonergic psychedelics as psychiatric medicines deepens, so does the pressure to better understand how these compounds act on the brain. We used a double-blind, placebo-controlled, crossover design and administered lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and d-amphetamine in 25 healthy participants. By using spectral dynamic causal...
Psychiatric News
April 23, 2024
Terri D’arrigo
announced in April that the Food and Drug Administration (FDA) approved the antipsychotic Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone has been approved for the acute treatment of schizophrenia since 2009. The approval was based on a phase 3 clinical trial of 414 adults with a history of bipolar I disorder....
Translational Psychiatry
April 15, 2024
Nathan Allen, Aron Jeremiah, Robin J Murphy et al.
15 citations
Microdosing psychedelic drugs at a level below the threshold to induce hallucinations is an increasingly common lifestyle practice. However, the effects of microdosing on sleep have not been previously reported. Here, we report results from a Phase 1 randomized controlled trial in which 80 healthy adult male volunteers received a 6-week course of either LSD (10 µg) or placebo with doses...